Transmural distribution of intramyocardial pressure measured by micropipette technique

1985 ◽  
Vol 249 (6) ◽  
pp. H1216-H1223 ◽  
Author(s):  
F. W. Heineman ◽  
J. Grayson
Keyword(s):  
Cardiac Cycle ◽  
Regression Line ◽  
Cardiac Performance ◽  
Aortic Constriction ◽  
Response Characteristics ◽  
Intramyocardial Pressure ◽  
In Vitro Response ◽  
Dynamic Response Characteristics

A technique is presented for measuring intramyocardial pressure (IMP) in beating hearts using the servo-nulling pressure transducer equipped with polyethylene micropipettes (ID less than 12 micron). The static and dynamic response characteristics of the system were tested in a pressurized, saline-filled container as well as in a pressurized, hollow, gelatin cylinder. The system was then used to measure IMP in vivo in the hearts of 12 dogs during stable cardiac performance and with aortic constriction. In vitro response characteristics were found to be satisfactory for accurate reproduction of cardiovascular waveforms. Peak systolic IMP was not found to exceed the simultaneously recorded left intraventricular pressure (LVP). Furthermore, the slope of the regression line relating the IMP to LVP during systole is linearly related (slope 0.98) to the depth of the micropipette tip in the ventricular wall, as normalized to total wall thickness. Diastolic IMP ranged between 1 +/- 1 (minimum during the cardiac cycle) and 4 +/- 2 mmHg (end diastolic) at associated LVP of 2 +/- 2 and 5 +/- 2 mmHg (mean +/- SD), respectively.

scholarly journals Hypertrophy-Reduced Autophagy Causes Cardiac Dysfunction by Directly Impacting Cardiomyocyte Contractility

Cells ◽  
2021 ◽  
Vol 10 (4) ◽  
pp. 805
Author(s):  
Christiane Ott ◽  
Tobias Jung ◽  
Sarah Brix ◽  
Cathleen John ◽  
Iris R. Betz ◽  
...  
Keyword(s):  
Cardiomyocyte Hypertrophy ◽  
Aortic Constriction ◽  
Cell Contractility ◽  
Neonatal Cardiomyocytes ◽  
Cardiomyocyte Contractility ◽  
Cardioprotective Effects ◽  
Modified Proteins ◽  
Cardiomyocyte Autophagy

Cardiac remodeling and contractile dysfunction are leading causes in hypertrophy-associated heart failure (HF), increasing with a population’s rising age. A hallmark of aged and diseased hearts is the accumulation of modified proteins caused by an impaired autophagy-lysosomal-pathway. Although, autophagy inducer rapamycin has been described to exert cardioprotective effects, it remains to be shown whether these effects can be attributed to improved cardiomyocyte autophagy and contractility. In vivo hypertrophy was induced by transverse aortic constriction (TAC), with mice receiving daily rapamycin injections beginning six weeks after surgery for four weeks. Echocardiographic analysis demonstrated TAC-induced HF and protein analyses showed abundance of modified proteins in TAC-hearts after 10 weeks, both reduced by rapamycin. In vitro, cardiomyocyte hypertrophy was mimicked by endothelin 1 (ET-1) and autophagy manipulated by silencing Atg5 in neonatal cardiomyocytes. ET-1 and siAtg5 decreased Atg5–Atg12 and LC3-II, increased natriuretic peptides, and decreased amplitude and early phase of contraction in cardiomyocytes, the latter two evaluated using ImageJ macro Myocyter recently developed by us. ET-1 further decreased cell contractility in control but not in siAtg5 cells. In conclusion, ET-1 decreased autophagy and cardiomyocyte contractility, in line with siAtg5-treated cells and the results of TAC-mice demonstrating a crucial role for autophagy in cardiomyocyte contractility and cardiac performance.

In Vivo vs. In Vitro Response Time of Trancutaneous Po2Electrodes A comparison of four devices in newborn infants

1978 ◽  
Vol 22 ◽  
pp. 40-48 ◽  
Author(s):  
H. T. Versmold ◽  
O. Linderkamp ◽  
K. H. Stuffer ◽  
M. Holzmann ◽  
K. P. Riegel
Keyword(s):  
Response Time ◽  
Newborn Infants ◽  
In Vitro Response

Rapid Differentiation of a Rare Subset of Adult Human Lin−CD34−CD38− Cells Stimulated by Multiple Growth Factors In Vitro

Blood ◽  
1999 ◽  
Vol 94 (6) ◽  
pp. 1926-1932 ◽  
Author(s):  
Tomoaki Fujisaki ◽  
Marc G. Berger ◽  
Stefan Rose-John ◽  
Connie J. Eaves
Keyword(s):  
Growth Factors ◽  
Fold Increase ◽  
Semisolid Medium ◽  
Response Characteristics ◽  
Adult Human ◽  
Liquid Suspension ◽  
Normal Duration ◽  
Necessary And Sufficient

Abstract Recently, several reports of lineage-negative (lin−) CD34− cells with in vivo hematopoietic activity have focused interest on the properties and growth factor response characteristics of these cells. We have now identified a combination of 5 growth factors that are necessary and sufficient to stimulate a marked mitogenic and differentiation response by a subset of human lin−CD34−CD38− cells present in normal adult human marrow and granulocyte colony-stimulating factor (G-CSF)–mobilized blood. Less than 0.1% of the cells in highly purified (including doubly sorted) lin−CD34−CD38− cells from these 2 sources formed colonies directly in semisolid medium or generated such cells after 6 weeks in long-term culture. Nevertheless, approximately 1% of the same lin−CD34−CD38− cells were able to proliferate rapidly in serum-free liquid suspension cultures containing human flt-3 ligand, Steel factor, thrombopoietin, interleukin-3 (IL-3), and hyper–IL-6 to produce a net 28- ± 8-fold increase in total cells within 10 days. Of the cells present in these 10-day cultures, 5% ± 2% were CD34+ and 2.5% ± 0.9% were erythroid, granulopoietic, megakaryocytopoietic, or multilineage colony-forming cells (CFC) (13 ± 7 CFC per lin−CD34−CD38− pre-CFC). In contrast to lin−CD34+CD38−cells, this response of lin−CD34−CD38− cells required exposure to all of the 5 growth factors used. Up to 1.7 × 105 lin−CD34− adult marrow cells failed to engraft sublethally irradiated NOD/SCID-β2M−/− mice. These studies demonstrate unique properties of a rare subset of lin−CD34−CD38− cells present in both adult human marrow and mobilized blood samples that allow their rapid proliferation and differentiation in vitro within an overall period of 3 to 4 weeks. The rapidity of this response challenges current concepts about the normal duration and coordinated control of these processes in adults.

scholarly journals IMMUNIZATION OF DISSOCIATED SPLEEN CELL CULTURES FROM NORMAL MICE

1967 ◽  
Vol 126 (3) ◽  
pp. 423-442 ◽  
Author(s):  
Robert I. Mishell ◽  
Richard W. Dutton
Keyword(s):  
Spleen Cell ◽  
Cell Cultures ◽  
Culture System ◽  
Cultured Cells ◽  
Inhibitory Effect ◽  
Initial Exposure ◽  
In Vitro Immunization ◽  
In Vitro Response

A culture system for cell suspensions from mouse spleens has been described. The system provides adequate conditions for in vitro immunization on initial exposure to heterologous erythrocytes. The in vitro response closely parallels that observed in vivo with respect to size, early kinetics, antigen dose, and the inhibitory effect of passive antibody. The response of cultured cells differs in two respects from that seen in vivo. There is an increase in the ability to discriminate between different varieties of homologous erythrocytes and the in vitro response does not appear to be limited by whatever mechanisms regulate the in vivo response.

scholarly journals The PPARα pathway in Vγ9Vδ2 T cell anergy

2014 ◽  
Vol 19 (4) ◽  
Author(s):  
Mary Poupot ◽  
Frédéric Boissard ◽  
Delphine Betous ◽  
Laure Bardouillet ◽  
Séverine Fruchon ◽  
...  
Keyword(s):  
T Cells ◽  
T Cell ◽  
Molecular Mechanisms ◽  
T Cell Response ◽  
T Cell Anergy ◽  
Pathway Activation ◽  
In Vitro Response ◽  
Vγ9vδ2 T Cells

AbstractPhosphoantigens (PAgs) activate Vγ9Vδ2 T lymphocytes, inducing their potent and rapid response in vitro and in vivo. However, humans and nonhuman primates that receive repeated injections of PAgs progressively lose their Vγ9Vδ2 T cell response to them. To elucidate the molecular mechanisms of this in vivo desensitization, we analyzed the transcriptome of circulating Vγ9Vδ2 T cells from macaques injected with PAg. We showed that three PAg injections induced the activation of the PPARα pathway in Vγ9Vδ2 T cells. Thus, we analyzed the in vitro response of Vγ9Vδ2 T cells stimulated with a PPARα agonist. We demonstrated that in vitro PPARα pathway activation led to the inhibition of the BrHPP-induced activation and proliferation of human Vγ9Vδ2 T cells. Since the PPARα pathway is involved in the antigen-selective desensitization of human Vγ9Vδ2 T cells, the use of PPARα inhibitors could enhance cancer immunotherapy based on Vγ9Vδ2 T cells.

Correlations between in vivo resistance to Fusarium and in vitro response to fungal elicitors and toxic substances in carnation

1985 ◽  
Vol 70 (1) ◽  
pp. 42-47 ◽  
Author(s):  
M. Buiatti ◽  
A. Scala ◽  
P. Bettini ◽  
G. Nascari ◽  
R. Morpurgo ◽  
...  
Keyword(s):  
Toxic Substances ◽  
Fungal Elicitors ◽  
In Vitro Response

In vivo and in vitro response to octreotide LAR in a TSH-secreting adenoma: characterization of somatostatin receptor expression and role of subtype 5

Pituitary ◽  
2010 ◽  
Vol 14 (2) ◽  
pp. 141-147 ◽  
Author(s):  
Federico Gatto ◽  
Federica Barbieri ◽  
Lara Castelletti ◽  
Marica Arvigo ◽  
Alessandra Pattarozzi ◽  
...  
Keyword(s):  
Somatostatin Receptor ◽  
Receptor Expression ◽  
Octreotide Lar ◽  
In Vitro Response

scholarly journals Growth hormone-releasing hormone attenuates cardiac hypertrophy and improves heart function in pressure overload-induced heart failure

2017 ◽  
Vol 114 (45) ◽  
pp. 12033-12038 ◽  
Author(s):  
Iacopo Gesmundo ◽  
Michele Miragoli ◽  
Pierluigi Carullo ◽  
Letizia Trovato ◽  
Veronica Larcher ◽  
...  
Keyword(s):  
Heart Failure ◽  
Growth Hormone ◽  
Cardiac Hypertrophy ◽  
Cardiac Function ◽  
Therapeutic Potential ◽  
Growth Hormone Releasing Hormone ◽  
Transverse Aortic Constriction ◽  
Aortic Constriction

It has been shown that growth hormone-releasing hormone (GHRH) reduces cardiomyocyte (CM) apoptosis, prevents ischemia/reperfusion injury, and improves cardiac function in ischemic rat hearts. However, it is still not known whether GHRH would be beneficial for life-threatening pathological conditions, like cardiac hypertrophy and heart failure (HF). Thus, we tested the myocardial therapeutic potential of GHRH stimulation in vitro and in vivo, using GHRH or its agonistic analog MR-409. We show that in vitro, GHRH(1-44)NH2 attenuates phenylephrine-induced hypertrophy in H9c2 cardiac cells, adult rat ventricular myocytes, and human induced pluripotent stem cell-derived CMs, decreasing expression of hypertrophic genes and regulating hypertrophic pathways. Underlying mechanisms included blockade of Gq signaling and its downstream components phospholipase Cβ, protein kinase Cε, calcineurin, and phospholamban. The receptor-dependent effects of GHRH also involved activation of Gαs and cAMP/PKA, and inhibition of increase in exchange protein directly activated by cAMP1 (Epac1). In vivo, MR-409 mitigated cardiac hypertrophy in mice subjected to transverse aortic constriction and improved cardiac function. Moreover, CMs isolated from transverse aortic constriction mice treated with MR-409 showed improved contractility and reversal of sarcolemmal structure. Overall, these results identify GHRH as an antihypertrophic regulator, underlying its therapeutic potential for HF, and suggest possible beneficial use of its analogs for treatment of pathological cardiac hypertrophy.

Sign in / Sign up

Export Citation Format

Share Document